Abilities to manage HCV-infection morbidity
Abstract
Russian system of medical care for patients with chronic hepatitis C does not allow to control the epidemic process. It is necessary to establish standards for diagnosis and treatment of hepatitis C within the framework of compulsory health insurance. It is necessary to change the terms of the delivery of medical care by including therapeutic and gastroenterology services in the medical care of patients with chronic viral hepatitis, as well as the implementation of that medical care to the outpatient care and day care therapy, infectious and gastrointestinal profiles. Mandatory condition of effective financial expenditures is also the formation of an effective antimonopoly regulation of the pharmaceutical market and price regulation on diagnostic equipment and medicines.
About the Authors
P. O. Bogomolov
M.F. Vladimirskiy Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
M. V. Matsievich
M.F. Vladimirskiy Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
A. O. Bueverov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. N. Kudryavtseva
M.F. Vladimirskiy Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
References
1. Богомолов П.О., Буеверов А.О., Дубинина Н.В. [и др.] Эффективность лечения больных хроническим гепатитом С с 1-м генотипом вируса стандартным интерфероном-альфа // Клин. перспект. гастроэнтерол. гепатол. 2011. № 6. С. 17-22.
2. Богомолов П.О., Буеверов А.О., Мациевич М. В. [и др.] Возможности повышения эффективности противовирусной терапии больных хроническим гепатитом С, инфицированных 3-м генотипом вируса // Инфекционные болезни. 2012. Т. 10, № 2. С. 8-14.
3. Корабельникова М.И., Кудрявцева Е.Н., Богомолов П.О. [и др.] Генетическое разнообразие вируса гепатита С на территории Московской области // Гепатология сегодня: материалы XII Российской конференции. М., 2007. С. 37.
4. Об организации медицинской помощи больным, страдающим хроническими вирусными гепатитами в Московской области: приказ МЗ Московской области от 27.11.2013 г. № 1474.
5. Об установлении схем ведения пациентов в медицинских организациях, реализующих Московскую областную программу обязательного медицинского страхования: приказ Министерства здравоохранения Московской области от 31.10.2013 г. № 1338.
6. Об утверждении долгосрочной целевой программы Московской области «Профилактика преступлений и иных правонарушений на территории Московской области на 2009-2011 годы: постановление Правительства Московской области от 30 мая 2008 г. № 403/19.
7. Шахгильдян И.В., Ясинский А.А., Михайлов М.И. [и др.] Хронические вирусные гепатиты в Российской Федерации // Клинико-эпидемиологические и этно-экологические проблемы заболеваний органов пищеварения: материалы восьмой Восточно-Сибирской гастроэнтерологической конференции. Красноярск, 2008. С. 246-253.
8. Aspinall A., Corson S., Doyle J. [et al.] Treatment of HCV infection among people who are actively injecting drugs: a systematic review and meta-analysis // Clin. Infect. Dis. 2013. Vol. 57, Suppl. 2. P. S80-S89.
9. Dore GJ. The changing therapeutic landscape for hepatitis C // Med. J. Aust. 2012. Vol. 196. P. 629-632.
10. Gane E.J., Stedman C.A., Hyland R.H. [et al.] Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C // New Engl. J. Med. 2013. Vol. 368. P. 34-44.
11. Grebely J., Raffa J.D., Lai C. [et al.] Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents // J. Viral. Hepat. 2009. Vol. 16. P. 352-358.
12. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs // J. Infec. Dis. 2011. Vol. 204. P. 74-83.
13. Hellard M., Jenkinson R., Higgs P [et al.] Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia // Med. J. Aust. 2012. Vol. 196. P. 638-641.
14. Iverson J., Maher L. Australian Needle and Syringe Program National Data Report 2007-2011. Kensington, Australia: The Kirby Institute, 2012.
15. Jacobson I.M., McHutchison J.G., Dusheiko G. [et al.] Telaprevir for previously untreated chronic hepatitis C virus infection // N. Engl. J. Med. 2011. Vol. 364. P 2405-2416.
16. Ly K.N., Xing J., Klevens R.M. [et al.] The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 // Annals of Internal Medicine. 2012. Vol. 156. P. 271-278.
17. Martin N.K., Miners A., Vickerman P. [et al.] The cost-effectiveness of HCV antiviral treatment for injecting drug user populations // Hepatology. 2012. Vol. 55. P. 49-57.
18. Martin N.K., Vickerman P, Foster G.R. [et al.] Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility // J. Hepatol. 2011. Vol. 54. P 1137-1144.
19. Martin N.K., Vickerman P., Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users // J. Theor. Biol. 2011. Vol. 274. P. 58-66.
20. Mehta S.H., Astemborski J., Kirk G.D. [et al.] Changes in blood-borne infection risk among injection drug users // J. Infec. Dis. 2011. Vol. 203. P. 587-594.
21. Poordad F., Lawitz E., Kowdley K.V. [et al.] Exploratory study of oral combination antiviral therapy for hepatitis C // New Engl. J. Med. 2013. Vol. 368. P. 45-53.
22. Poordad F., McCone J., Bacon B.R. [et al.] Boceprevir for untreated chronic HCV genotype 1 infection // New Engl. J. Med. 2011. Vol. 364. P. 1195-1206.
23. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection // Lancet Infec. Dis. 2005. No. 5. P. 558-567.
24. Turner K., Hutchinson S., Craine N. [et al.] The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence // Addiction. 2011. Vol. 106. P 1978-1988.
25. Van Den Berg C., Smit C., Brussel G.V. [et al.] Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users // Addiction. 2007. Vol. 102. P. 1454-1462.
26. Van der Meer A.J. Achieving sustained virological response: what>s the impact on further hepatitis C virus-related disease? // Expert Rev. Gastroenterol. Hepatol. 2015. Vol. 12. P. 1-8.
27. Vickerman P., Martin N., Hickman M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere // Drug Alcohol Depend. 2011. Vol. 113. P. 83-85.
28. Zeiler I., Langlands T., Murray J.M., Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs // Drug Alcohol Depend. 2010. Vol. 110. P. 228-233.
Review
For citations:
Bogomolov P.O., Matsievich M.V., Bueverov A.O., Kudryavtseva E.N. Abilities to manage HCV-infection morbidity. Pacific Medical Journal. 2015;(1):16-20. (In Russ.)
Views:
238
Email this article 